ZAS Pharma Ltd. proudly observes Epilepsy Awareness Month in November 2023, collaborating with the esteemed doctors of Bangabandhu Sheikh Mujib Medical University through their ‘Named Patient Access’ initiative. In a collective effort, they aim to heighten awareness about rare diseases, offering crucial support to those facing these challenges. Heartfelt gratitude is extended to the dedicated doctors and the ZAS team for their unwavering commitment to this cause. The ‘Named Patient Access’ division remains steadfast in its mission to bridge gaps and provide essential support for rare disease patients in Bangladesh, emphasizing ZAS Pharma’s dedication to making a meaningful impact in healthcare.
More Releases
ZAS Corporation Introduces Uro-Vaxom to Bangladesh: A Milestone in UTI Prevention
ZAS Corporation proudly launched Uro-Vaxom, an advanced immunotherapeutic solution by OM Pharma, Switzerland,...
|
21 Nov, 2024
ZAS Corporation Hosts Virtual CME on Kidney Transplant Induction Therapy
In collaboration with the Nephrology Department at the National Institute of Kidney Diseases & Urology...
|
04 Nov, 2024
ZAS Corporation Showcases Commitment to Oncology Care at MOSB Congress 2024
ZAS Corporation proudly participated in the prestigious MOSB Congress 2024, reaffirming its dedication...
|
22 Oct, 2024
ZAS Corporation Proudly Sponsors the 178th World Anesthesia Day Celebration with Bangladesh Society of Anaesthesiologists, Critical Care and Pain Physicians
ZAS Corporation was honored to serve as the core sponsor of the 178th World Anesthesia Day celebration,...
|
19 Oct, 2024
ZAS Corporation Celebrates 19th Anniversary with Team Participation
ZAS Corporation proudly marked its 19th anniversary, celebrating nearly two decades of excellence, innovation,...
|
16 Oct, 2024
Morinaga Research Centre Japan Visits Bangladesh to Strengthening Global Collaborations
We are thrilled to have welcomed our partners from the Morinaga Research Centre, Japan, to Bangladesh....
|
16 Oct, 2024
ZAS Corporation Secures Trademark for DECA Brand
We are proud to announce that ZAS Corporation Ltd. has officially secured the trademark for our brand...
|
05 Oct, 2024
ZAS Corporation Obtains Trademark for Protimeal Brand
We are delighted to announce that ZAS Corporation has successfully obtained the trademark for our brand...
|
05 Oct, 2024
ZAS Corporation Successfully Launches Celltrion Biosimilars in Bangladesh
We are proud to announce the successful launch of Celltrion’s biosimilar products in Bangladesh,...
|
31 Aug, 2024
ZAS Corporation Ltd. Unveils Vision for the Next Decade in Oncology at Sales Conference
Dhaka, Bangladesh – ZAS Corporation Ltd., a leading pharmaceutical company with a strong focus on oncology,...
|
07 Aug, 2024